DBV Technologies (NASDAQ:DBVT) Sees Large Volume Increase – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) saw strong trading volume on Wednesday . 626,482 shares traded hands during mid-day trading, an increase of 118% from the previous session’s volume of 287,370 shares.The stock last traded at $18.56 and had previously closed at $18.16.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Citizens Jmp upped their price target on DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a research note on Friday, May 1st. Guggenheim reaffirmed a “buy” rating and issued a $51.00 price target on shares of DBV Technologies in a research note on Monday, May 4th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, DBV Technologies presently has a consensus rating of “Moderate Buy” and an average price target of $40.25.

DBV Technologies Stock Up 3.1%

The company has a fifty day simple moving average of $20.05 and a 200 day simple moving average of $19.33. The firm has a market capitalization of $1.11 billion, a P/E ratio of -4.18 and a beta of -0.96.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%.The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. As a group, equities analysts expect that DBV Technologies S.A. will post -0.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

Several hedge funds have recently added to or reduced their stakes in DBVT. Artisan Partners Limited Partnership bought a new position in shares of DBV Technologies during the third quarter valued at $519,000. DLD Asset Management LP bought a new position in shares of DBV Technologies during the third quarter valued at $250,000. UBS Group AG lifted its holdings in shares of DBV Technologies by 165,347.3% during the fourth quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after purchasing an additional 244,714 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of DBV Technologies during the fourth quarter valued at $479,000. Finally, Two Sigma Investments LP bought a new position in shares of DBV Technologies during the third quarter valued at $167,000. 71.74% of the stock is owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.